SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
December 4, 2012
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
Irvine, California 92618
(Address of principal executive offices) (Zip Code)
(Registrants telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 7.01 Regulation FD Disclosure.
On December 4, 2012, Frederick Furry, Chief Operating Officer and Chief Financial Officer of Biolase, Inc. (the Company) will deliver a presentation at the Canaccord Genuity 2012 Medical Technology & Diagnostics Forum that will include a written communication comprised of slides. The slides from the presentation are attached hereto as Exhibit 99.1, and are hereby incorporated by reference.
A copy of the slides will be available for viewing and download at http://www.biolase.com/investors until December 18, 2012.
Item 9.01 Financial Statements and Exhibits.
99.1 Presentation material from the Canaccord Genuity 2012 Medical Technology & Diagnostics Forum, dated December 4, 2012.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.